• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

马尔堡病毒病食蟹猴模型的特征描述和治疗性药物测试时机评估。

Characterization of the Cynomolgus Macaque Model of Marburg Virus Disease and Assessment of Timing for Therapeutic Treatment Testing.

机构信息

United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.

Geneva Foundation, Tacoma, WA 98402, USA.

出版信息

Viruses. 2023 Nov 28;15(12):2335. doi: 10.3390/v15122335.

DOI:10.3390/v15122335
PMID:38140576
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10748006/
Abstract

Marburg virus (MARV) causes severe disease and high mortality in humans. The objective of this study was to characterize disease manifestations and pathogenesis in cynomolgus macaques exposed to MARV. The results of this natural history study may be used to identify features of MARV disease useful in defining the ideal treatment initiation time for subsequent evaluations of investigational therapeutics using this model. Twelve cynomolgus macaques were exposed to a target dose of 1000 plaque-forming units MARV by the intramuscular route, and six control animals were mock-exposed. The primary endpoint of this study was survival to Day 28 post-inoculation (PI). Anesthesia events were minimized with the use of central venous catheters for periodic blood collection, and temperature and activity were continuously monitored by telemetry. All mock-exposed animals remained healthy for the duration of the study. All 12 MARV-exposed animals (100%) became infected, developed illness, and succumbed on Days 8-10 PI. On Day 4 PI, 11 of the 12 MARV-exposed animals had statistically significant temperature elevations over baseline. Clinically observable signs of MARV disease first appeared on Day 5 PI, when 6 of the 12 animals exhibited reduced responsiveness. Ultimately, systemic inflammation, coagulopathy, and direct cytopathic effects of MARV all contributed to multiorgan dysfunction, organ failure, and death or euthanasia of all MARV-exposed animals. Manifestations of MARV disease, including fever, systemic viremia, lymphocytolysis, coagulopathy, and hepatocellular damage, could be used as triggers for initiation of treatment in future therapeutic efficacy studies.

摘要

马尔堡病毒(MARV)可导致人类严重疾病和高死亡率。本研究的目的是描述感染 MARV 的食蟹猴的疾病表现和发病机制。本自然史研究的结果可用于确定 MARV 疾病的特征,这些特征可用于定义后续使用该模型评估研究性治疗药物的理想治疗起始时间。12 只食蟹猴通过肌肉途径暴露于 1000 个噬菌斑形成单位 MARV 的目标剂量,6 只对照动物进行模拟暴露。本研究的主要终点是接种后第 28 天(PI)的存活。通过使用中心静脉导管定期采集血液来尽量减少麻醉事件,并通过遥测连续监测体温和活动。所有模拟暴露的动物在研究期间均保持健康。所有 12 只 MARV 暴露的动物(100%)均感染、发病,并在 PI 的第 8-10 天死亡。在 PI 的第 4 天,11 只 MARV 暴露的动物的体温与基线相比有统计学意义的升高。MARV 疾病的临床可见症状于 PI 的第 5 天首次出现,当时 12 只动物中的 6 只表现出反应能力降低。最终,MARV 的全身炎症、凝血功能障碍和直接细胞病变作用均导致多器官功能障碍、器官衰竭以及所有 MARV 暴露的动物死亡或安乐死。MARV 疾病的表现,包括发热、全身病毒血症、淋巴细胞溶解、凝血功能障碍和肝细胞损伤,可用作未来治疗效果研究中开始治疗的触发因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/4349dfc71f93/viruses-15-02335-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/c9237eefd629/viruses-15-02335-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/b3b655a074d7/viruses-15-02335-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/c47e14404c32/viruses-15-02335-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/cee116b4a2cf/viruses-15-02335-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/60eaa3d22384/viruses-15-02335-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/1c05671013e4/viruses-15-02335-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/52237b4cb913/viruses-15-02335-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/7be9d0317835/viruses-15-02335-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/a79ba812340a/viruses-15-02335-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/1a6706c1e0aa/viruses-15-02335-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/9d8d081e7aa9/viruses-15-02335-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/65bade47ea7d/viruses-15-02335-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/233a25dee974/viruses-15-02335-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/c5fd1d895a4c/viruses-15-02335-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/26a1ecc77957/viruses-15-02335-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/4349dfc71f93/viruses-15-02335-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/c9237eefd629/viruses-15-02335-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/b3b655a074d7/viruses-15-02335-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/c47e14404c32/viruses-15-02335-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/cee116b4a2cf/viruses-15-02335-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/60eaa3d22384/viruses-15-02335-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/1c05671013e4/viruses-15-02335-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/52237b4cb913/viruses-15-02335-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/7be9d0317835/viruses-15-02335-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/a79ba812340a/viruses-15-02335-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/1a6706c1e0aa/viruses-15-02335-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/9d8d081e7aa9/viruses-15-02335-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/65bade47ea7d/viruses-15-02335-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/233a25dee974/viruses-15-02335-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/c5fd1d895a4c/viruses-15-02335-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/26a1ecc77957/viruses-15-02335-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f14/10748006/4349dfc71f93/viruses-15-02335-g016.jpg

相似文献

1
Characterization of the Cynomolgus Macaque Model of Marburg Virus Disease and Assessment of Timing for Therapeutic Treatment Testing.马尔堡病毒病食蟹猴模型的特征描述和治疗性药物测试时机评估。
Viruses. 2023 Nov 28;15(12):2335. doi: 10.3390/v15122335.
2
Natural History of Marburg Virus Infection to Support Medical Countermeasure Development.支持医疗对策开发的马尔堡病毒感染自然史。
Viruses. 2022 Oct 18;14(10):2291. doi: 10.3390/v14102291.
3
Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges).病毒样颗粒疫苗接种可保护非人灵长类动物免受马尔堡病毒致死性气溶胶暴露(病毒样颗粒疫苗接种保护猕猴免受气溶胶攻击)。
Viruses. 2016 Apr 8;8(4):94. doi: 10.3390/v8040094.
4
Aerosol exposure to the angola strain of marburg virus causes lethal viral hemorrhagic Fever in cynomolgus macaques.安哥拉马尔堡病毒株气溶胶暴露导致食蟹猕猴发生致命性病毒性出血热。
Vet Pathol. 2010 Sep;47(5):831-51. doi: 10.1177/0300985810378597.
5
Virulence of Marburg Virus Angola Compared to Mt. Elgon (Musoke) in Macaques: A Pooled Survival Analysis.安哥拉马尔堡病毒的毒力与在猕猴中的姆特-Elgon(Musoke)病毒相比:一项汇总生存分析。
Viruses. 2018 Nov 21;10(11):658. doi: 10.3390/v10110658.
6
Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA.非人灵长类动物中的马尔堡病毒感染:脂质包裹的小干扰RNA的治疗性处理
Sci Transl Med. 2014 Aug 20;6(250):250ra116. doi: 10.1126/scitranslmed.3009706.
7
Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates.基于水疱性口炎病毒的马尔堡病毒疫苗在非人灵长类动物中的持久性。
PLoS One. 2014 Apr 23;9(4):e94355. doi: 10.1371/journal.pone.0094355. eCollection 2014.
8
Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses.重组蛋白丝状病毒疫苗可保护食蟹猴免受埃博拉、苏丹和马尔堡病毒的感染。
Front Immunol. 2021 Aug 18;12:703986. doi: 10.3389/fimmu.2021.703986. eCollection 2021.
9
Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus.瑞德西韦(GS-5734)对感染马尔堡病毒的食蟹猕猴有效。
J Infect Dis. 2020 Nov 9;222(11):1894-1901. doi: 10.1093/infdis/jiaa290.
10
Delayed Time-to-Treatment of an Antisense Morpholino Oligomer Is Effective against Lethal Marburg Virus Infection in Cynomolgus Macaques.反义吗啉代寡聚物延迟治疗对食蟹猴致命性马尔堡病毒感染有效。
PLoS Negl Trop Dis. 2016 Feb 22;10(2):e0004456. doi: 10.1371/journal.pntd.0004456. eCollection 2016 Feb.

引用本文的文献

1
Immunogenicity, Pathogenesis, and Host's Immuno-Responses to Marburg Virus Infection.马尔堡病毒感染的免疫原性、发病机制及宿主免疫反应
Pathogens. 2025 Mar 27;14(4):323. doi: 10.3390/pathogens14040323.
2
Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques.重组水疱性口炎病毒载体马尔堡疫苗在食蟹猴中的功效和免疫原性。
Viruses. 2024 Jul 24;16(8):1181. doi: 10.3390/v16081181.

本文引用的文献

1
WHO: Marburg Virus Outbreak Confirmed in Equatorial Guinea.世界卫生组织:赤道几内亚确认爆发马尔堡病毒疫情。
JAMA. 2023 Mar 28;329(12):969. doi: 10.1001/jama.2023.3199.
2
The re-emergence of Marburg virus Disease in West Africa: how prepared is the sub-region for preventing recurrent zoonotic outbreaks?马尔堡病毒病在西非再度出现:该次区域在预防人畜共患病再次爆发方面准备得如何?
Int J Infect Dis. 2023 May;130:28-30. doi: 10.1016/j.ijid.2023.03.001. Epub 2023 Mar 3.
3
Marburg virus outbreak: researchers race to test vaccines.马尔堡病毒爆发:研究人员竞相测试疫苗。
Nature. 2023 Feb;614(7949):603. doi: 10.1038/d41586-023-00468-5.
4
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.美国健康成年人中 chimpanzee 腺病毒 3 型载体马尔堡病毒(cAd3-Marburg)疫苗的安全性、耐受性和免疫原性:首次人体、1 期、开放性、剂量递增试验。
Lancet. 2023 Jan 28;401(10373):294-302. doi: 10.1016/S0140-6736(22)02400-X.
5
Natural History of Marburg Virus Infection to Support Medical Countermeasure Development.支持医疗对策开发的马尔堡病毒感染自然史。
Viruses. 2022 Oct 18;14(10):2291. doi: 10.3390/v14102291.
6
Marburg virus outbreak in 2022: a public health concern.2022年马尔堡病毒疫情:一个公共卫生问题。
Lancet Microbe. 2023 Jan;4(1):e9. doi: 10.1016/S2666-5247(22)00258-0. Epub 2022 Oct 6.
7
Development of a Well-Characterized Cynomolgus Macaque Model of Marburg Virus Disease for Support of Vaccine and Therapy Development.开发一种特征明确的马尔堡病毒病食蟹猴模型以支持疫苗和疗法开发。
Vaccines (Basel). 2022 Aug 14;10(8):1314. doi: 10.3390/vaccines10081314.
8
Detection of Marburg Virus Disease in Guinea.几内亚马尔堡病毒病的检测
N Engl J Med. 2022 Jun 30;386(26):2528-2530. doi: 10.1056/NEJMc2120183.
9
Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses.重组蛋白丝状病毒疫苗可保护食蟹猴免受埃博拉、苏丹和马尔堡病毒的感染。
Front Immunol. 2021 Aug 18;12:703986. doi: 10.3389/fimmu.2021.703986. eCollection 2021.
10
Marburg virus disease: A summary for clinicians.马尔堡病毒病:临床医生须知。
Int J Infect Dis. 2020 Oct;99:233-242. doi: 10.1016/j.ijid.2020.07.042. Epub 2020 Aug 3.